Search

Displaying results 2721 - 2730 of 4438 in total
  1. Drug

    Pomaglumetad methionil

    go.drugbank.com/drugs/DB05096
    Investigational

    Most currently approved antipsychotic medications work by affecting the neurotransmitters dopamine or serotonin. … For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed.

  2. Drug

    Difluprednate

    go.drugbank.com/drugs/DB06781
    ApprovedInvestigational

    Difluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or diflu...

  3. Drug

    3,4-Methylenedioxy-N-isopropylamphetamine

    go.drugbank.com/drugs/DB06112
    Experimental

    MDI-P has demonstrated potent anti-HIV activity. MDI-P has been shown to be effective in killing HIV in cell culture. HIV is the virus that causes acquired immune deficiency syndrome (AIDS). MDI-P is also a potential therapeutic agent fo...

  4. Drug

    Lipegfilgrastim

    go.drugbank.com/drugs/DB13200
    Approved

    Since July 2013, lipegfilgrastim is marketed by the EMA as Lonquex for subcutaneously injection, where it is administered once following cytotoxic chemotherapy for each chemotherapy cycle in adult patients

  5. Drug

    Inebilizumab

    go.drugbank.com/drugs/DB12530
    ApprovedInvestigational

    Inappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.

  6. Drug

    Tepotinib

    go.drugbank.com/drugs/DB15133
    ApprovedInvestigational

    Tepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February

  7. Drug

    Carbenoxolone

    go.drugbank.com/drugs/DB02329
    Experimental

    Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]

  8. Drug

    PIKA rabies vaccine

    go.drugbank.com/drugs/DB17963
    Investigational

    PIKA rabies vaccine is a novel vaccine developed by YS Biopharma.

  9. Drug

    2G7

    go.drugbank.com/drugs/DB18589
    Experimental

    2G7 is an anti-TGF-beta monoclonal antibody developed by Genentech.

  10. Drug

    Istradefylline

    go.drugbank.com/drugs/DB11757
    ApprovedInvestigational

    Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.